Risk of SARS-CoV-2 infection in patients with hematologic diseases receiving tixagevimab/cilgavimab as pre-exposure prophylaxis in most recent Omicron sublineages era

Risk of SARS-CoV-2 infection in patients with hematologic diseases receiving tixagevimab/cilgavimab as pre-exposure prophylaxis in most recent Omicron sublineages era

Objectives: Whether pre-exposure prophylaxis (PrEP) with tixagevimab/cilgavimab 150 mg/150 mg (T/C) in individuals with hematologic disease (HD) may lead to a reduced risk of SARS-CoV-2 breakthrough infection (BTI)/hospitalization, or death in the Omicron era remains to be established. Methods: An o...

Full description

Bibliographic Details
Main Authors: Alessandra Vergori, Alessandro Cozzi Lepri, Marta Chiuchiarelli, Valentina Mazzotta, Elisabetta Metafuni, Giulia Matusali, Valentina Siciliano, Jessica Paulicelli, Eleonora Alma, Agostina Siniscalchi, Simona Sica, Elisabetta Abruzzese, Massimo Fantoni, Andrea Antinori, Antonella Cingolani
Format: Article
Language:English
Published: Elsevier 2024-07-01
Series:International Journal of Infectious Diseases
Subjects:
SARS-CoV-2
COVID-19
Hematologic disease
Pre-exposure prophylaxis
Tixagevimab/cilgavimab
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971224001139

Internet

http://www.sciencedirect.com/science/article/pii/S1201971224001139

Similar Items